1. Home
  2. SSII vs ANNX Comparison

SSII vs ANNX Comparison

Compare SSII & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSII

SS Innovations International Inc.

HOLD

Current Price

$4.00

Market Cap

774.5M

Sector

N/A

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

N/A

Current Price

$5.39

Market Cap

812.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SSII
ANNX
Founded
N/A
2011
Country
India
United States
Employees
483
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
774.5M
812.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SSII
ANNX
Price
$4.00
$5.39
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
36.7K
2.0M
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$1.85
52 Week High
$11.87
$7.18

Technical Indicators

Market Signals
Indicator
SSII
ANNX
Relative Strength Index (RSI) 40.63 47.15
Support Level $3.75 $4.79
Resistance Level $5.14 $5.61
Average True Range (ATR) 0.21 0.29
MACD 0.02 -0.01
Stochastic Oscillator 27.08 48.32

Price Performance

Historical Comparison
SSII
ANNX

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company. It designs, manufactures, and markets a surgical robotic system called the SSi Mantra Surgical Robotic System (the SSi Mantra) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. Additionally, the company offers a suite of stapling, energy, and core instrumentation for its surgical systems, under the brand name of SSi Mudra.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: